WeightWatchers Clinic tirzepatide: November 2026 price and position
As of November 20, 2026, WeightWatchers Clinic is a brand route for tirzepatide: membership $25 first month, then $74 a month on a 12-month plan or $84 on a 6-month plan; "Cost of GLP-1 medications not included.". It sells or prescribes brand medication rather than compounded tirzepatide, so it has no place in this site’s compounded tirzepatide comparison.
Released · Last reviewed · how we verify
Brand prices for comparison
Bought direct, Zepbound vials cost $299 at 2.5 mg, $399 at 5 mg and $449 at 7.5–15 mg when each refill is within 45 days (otherwise $499 at 7.5 mg and $699 at 10–15 mg); Wegovy pens cost $349 a month and the Wegovy pill $149 to $299 by dose (NovoCare, read November 20, 2026; the Zepbound ladder is carried from October 15 because lilly.com refused automated reads). See the brand price page.
Limitations and what to check before you enroll
Brand Zepbound is FDA-approved. Through WeightWatchers Clinic you pay the manufacturer’s self-pay price, or your insurance copay, plus any fee WeightWatchers Clinic charges for its own service. Ask for that fee, what it includes and how it renews before you start. A clinician decides whether any GLP-1 is right for you.
Frequently asked
How much does WeightWatchers Clinic charge for tirzepatide?
As of November 20, 2026, WeightWatchers Clinic is a brand route for tirzepatide: membership $25 first month, then $74 a month on a 12-month plan or $84 on a 6-month plan; "Cost of GLP-1 medications not included.". It sells or prescribes brand medication rather than compounded tirzepatide, so it has no place in this site’s compounded tirzepatide comparison.
Is WeightWatchers Clinic’s tirzepatide FDA-approved?
WeightWatchers Clinic is a brand route: the brand medication it offers (Zepbound) is FDA-approved. Compounded tirzepatide from other programs is not FDA-approved and is not the same product.
Where do these WeightWatchers Clinic figures come from?
From WeightWatchers Clinic’s own page (first-party read, November 20, 2026), converted to an all-in month-to-month figure (medication plus any required recurring fee, before tax). The source link and read date are listed below, and the same figures are in the open dataset.
Sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026; read November 20, 2026)
- Federal Register 91 FR 23431: proposed 503B bulks-list decision for semaglutide, tirzepatide and liraglutide (May 1, 2026; no final notice found as of November 20, 2026)
- Zepbound (tirzepatide) prescribing information on DailyMed (read November 20, 2026)
- Wegovy (semaglutide) prescribing information on DailyMed (read November 20, 2026)
- WeightWatchers Clinic pricing page (read November 20, 2026)